Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112580 · ClinicalTrials.gov registry record · Phase 2
MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00112580 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 27 participants.
The verdict
NCT00112580, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as MDX-010, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well MDX-010 works in treating patients with stage IV pancreatic cancer that cannot be removed by surgery.
Interventions
- BIOLOGICAL ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2005-07-31 |
| Est. Completion | 2009-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00112580
The ClinicalTrials.gov registry entry for NCT00112580 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ipilimumab is the first listed.
NCT00112580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00112580 about?
NCT00112580 is a clinical study titled "MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery". RATIONALE: Biological therapies, such as MDX-010, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well MDX-010 works in treating patients with stage IV pancreatic cancer that cannot be removed by surgery.
What is the current status of trial NCT00112580?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2005-07-31. Estimated completion is 2009-06-30.
What interventions are being tested in trial NCT00112580?
The interventions under investigation include: ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00112580?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.